• head_banner_01

Factory For Lovastatin - Impurities of Amino Acid Used for Synthesize Protein – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We're committed to furnishing easy,time-saving and money-saving one-stop purchasing support of consumer for Neratinib, Lenvatinib, 1-(4-Methoxyphenyl)Methanamine, If you are looking for a good quality, fast delivery, best after service and good price supplier in China for long-term business relationship, we will be your best choice.
Factory For Lovastatin - Impurities of Amino Acid Used for Synthesize Protein – Gentolex Detail:

Product Detail

NO

Products

CAS No

Key Quality Indicator

Purity

Max.

impurity

Total solvent residue

Moisture

1

Fmoc-β-Ala-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

2

Fmoc-D-Ala-D-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

3

Fmoc-β-Ala-D-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

4

Fmoc-Arg(pbf)-Arg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

5

Fmoc-β-Ala-Arg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

6

Fmoc-D-Arg(pbf)-D-Arg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

7

Fmoc-β-Ala-D-Arg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

8

Fmoc-HomoArg(pbf)-HomoArg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

9

Fmoc-β-Ala-HomoArg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

10

Fmoc-Asn(Trt)-Asn(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

11

Fmoc-β-Ala-Asn(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

12

Fmoc-Asp(OtBu)-Asp(OtBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

13

Fmoc-β-Ala-Asp(OtBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

14

Fmoc-Cys(Trt)-Cys(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

15

Fmoc-β-Ala-Cys(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

16

Fmoc-Cys(Acm)-Cys(Acm)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

17

Fmoc-β-Ala-Cys(Acm)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

18

Fmoc-Gln(Trt)-Gln(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

19

Fmoc-β-Ala-Gln(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

20

Fmoc-Glu(OtBu)-Glu(OtBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

21

Fmoc-β-Ala-Glu(OtBu)-OH.H2O

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

22

Fmoc-β-Ala-Gly-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

23

Fmoc-His(Trt)-His(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

24

Fmoc-β-Ala-His(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

25

Fmoc-Ile-Ile-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

26

Fmoc-β-Ala-Ile-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

27

Fmoc-Leu-Leu-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

28

Fmoc-β-Ala-Leu-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

29

Fmoc-D-Leu-D-Leu-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

30

Fmoc-β-Ala-D-Leu-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

31

Fmoc-Lys(Boc)-Lys(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

32

Fmoc-β-Ala-Lys(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

33

Fmoc-Lys(Alloc)-Lys(Alloc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

34

Fmoc-β-Ala-Lys(Alloc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

35

Fmoc-Met-Met-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

36

Fmoc-β-Ala-Met-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

37

Fmoc-Orn(Boc)-Orn(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

38

Fmoc-β-Ala-Orn(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

39

Fmoc-Phe-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

40

Fmoc-β-Ala-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

41

Fmoc-D-Phe-D-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

42

Fmoc-β-Ala-D-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

43

Fmoc-Pro-Pro-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

44

Fmoc-β-Ala-Pro-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

45

Fmoc-Ser(tBu)-Ser(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

46

Fmoc-β-Ala-Ser(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

47

Fmoc-Ser(Trt)-Ser(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

48

Fmoc-β-Ala-Ser(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

49

Fmoc-Thr(tBu)-Thr(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

50

Fmoc-β-Ala-Thr(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

51

Fmoc-Trp(Boc)-Trp(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

52

Fmoc-β-Ala-Trp(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

53

Fmoc-D-Trp(Boc)-D-Trp(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

54

Fmoc-β-Ala-D-Trp(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

55

Fmoc-Tyr(tBu)-Tyr(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

56

Fmoc-β-Ala-Tyr(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

57

Fmoc-D-Tyr(Et)-D-Tyr(Et)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

58

Fmoc-β-Ala-D-Tyr(Et)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

59

Fmoc-Tyr(Me)-Tyr(Me)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

60

Fmoc-β-Ala-Tyr(Me)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

61

Fmoc-Val-Val-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

62

Fmoc-β-Ala-Val-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

63

Fmoc-D-Cit-D-Cit-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

64

Fmoc-β-Ala-D-Cit-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

65

Fmoc-β-Ala-Dab-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

66

Fmoc-(3-(2-naphthyl)-D-Ala)2-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

67

Fmoc-β-Ala-3-(2-naphthyl)-D-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

68

Fmoc-(3-(3-pyridinyl)-D-Ala)2-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

69

Fmoc-β-Ala-3-(3-pyridinyl)-D-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

70

Fmoc-(4-chloro-D-Phe)2-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

71

Fmoc-β-Ala-4-chloro-D-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

72

Fmoc-(D-4Aph(tBuCbm))2-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

73

Fmoc-β-Ala-D-4Aph(tBuCbm)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

74

Fmoc-Aph(L-Hor)-Aph(L-Hor)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

75

Fmoc-β-Ala-Aph(L-Hor)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

76

Fmoc-Lys(iPr,Boc)-Lys(iPr,Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

77

Fmoc-β-Ala-Lys(iPr,Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

78

Fmoc-β-Ala-AEEA-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

79

Fmoc-Aib-Aib-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

80

Fmoc-β-Ala-Aib-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

81

Fmoc-Arg-OH

91000-69-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

82

H-Arg(pbf)-OH

200115-86-2

≥98.0%

≤1.0%

≤8.0%

≤2.0%

83

Fmoc-D-Arg-OH

130752-32-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

84

H-D-Arg(pbf)-OH

200116-81-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

85

Fmoc-HomoArg-OH.HCl

208174-14-5

≥98.0%

≤1.0%

≤8.0%

≤2.0%

86

H-HomoArg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

87

Fmoc-D-HomoArg-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

88

H-D-HomoArg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

89

Fmoc-Asn-OH

71989-16-7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

90

H-Asn(Trt)-OH

132388-58-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

91

Fmoc-Asp-OH

119062-05-4

≥98.0%

≤1.0%

≤8.0%

≤2.0%

92

H-Asp(OtBu)-OH

3057-74-7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

93

Fmoc-Cys-OH

135248-89-4

≥98.0%

≤1.0%

≤8.0%

≤2.0%

94

H-Cys(Trt)-OH

2799/7/7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

95

H-Cys(Acm)-OH.HCl

28798-28-9

≥98.0%

≤1.0%

≤8.0%

≤2.0%

96

Fmoc-Gln-OH

71989-20-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

97

H-Gln(Trt)-OH

102747-84-2

≥98.0%

≤1.0%

≤8.0%

≤2.0%

98

Fmoc-Glu-OH

121343-82-6

≥98.0%

≤1.0%

≤8.0%

≤2.0%

99

H-Glu(OtBu)-OH.H2O

2419-56-9

≥98.0%

≤1.0%

≤8.0%

≤2.0%

100

Fmoc-His-OH

116611-64-4

≥98.0%

≤1.0%

≤8.0%

≤2.0%

101

H-His(Trt)-OH

35146-32-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

102

Boc-His-OH

17791-52-5

≥98.0%

≤1.0%

≤8.0%

≤2.0%

103

Fmoc-Lys-OH

105047-45-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

104

H-Lys(Boc)-OH

2418-95-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

105

H-Lys(Alloc)-OH

6298/3/9

≥98.0%

≤1.0%

≤8.0%

≤2.0%

106

Fmoc-Orn-OH.HCl

201046-57-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

107

H-Orn(Boc)-OH

13650-49-2

≥98.0%

≤1.0%

≤8.0%

≤2.0%

108

Fmoc-Ser-OH

73724-45-5

≥98.0%

≤1.0%

≤8.0%

≤2.0%

109

H-Ser(tBu)-OH

18822-58-7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

110

H-Ser(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

111

Fmoc-Thr-OH.H2O

73731-37-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

112

H-Thr(tBu)-OH

4378-13-6

≥98.0%

≤1.0%

≤8.0%

≤2.0%

113

Fmoc-Trp-OH

35737-15-6

≥98.0%

≤1.0%

≤8.0%

≤2.0%

114

H-Trp(Boc)-OH

146645-63-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

115

Fmoc-D-Trp-OH

86123-11-7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

116

H-D-Trp(Boc)-OH

201290-11-1

≥98.0%

≤1.0%

≤8.0%

≤2.0%

117

Fmoc-Tyr-OH

92954-90-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

118

H-Tyr(tBu)-OH

18822-59-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

119

Fmoc-D-Tyr-OH

112883-29-1

≥98.0%

≤1.0%

≤8.0%

≤2.0%

120

H-D-Tyr(Et)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

121

H-Tyr(Me)-OH.HCl

67423-44-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

122

Fmoc-D-4Aph(Cbm)-OH

324017-22-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

123

H-D-4Aph(tBuCbm)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

124

Fmoc-Lys(iPr)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

125

H-Lys(iPr,Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

About

Compensation

Gentolex provide great quality products, if any product quality is raised by the client within the required time frame with sufficient evidences, we will provide necessary analysis and evaluation to trigger the procedures of compensations.

Production

The capacities of pharmaceutical products reached tons grade, the capacities of chemical products reach 100tons+ grade, the capabilities are well equipped to serve clients worldwide.

Research and Development

Every year, there is plan set up by the R&D team to develop different new products, when targets set, every member in the team will have to carry on with KPI responsibility and with incentive policy.


Product detail pictures:

Factory For Lovastatin - Impurities of Amino Acid Used for Synthesize Protein – Gentolex detail pictures


Related Product Guide:

We always believe that one's character decides products' quality, the details decides products' high-quality ,together with the REALISTIC,EFFICIENT AND INNOVATIVE crew spirit for Factory For Lovastatin - Impurities of Amino Acid Used for Synthesize Protein – Gentolex , The product will supply to all over the world, such as: Eindhoven, Egypt, Las Vegas, Today, We are with great passion and sincerity to further fulfill our global customers' needs with good quality and design innovation. We fully welcome customers from all over the world to establish stable and mutually beneficial business relationships, to have a bright future together.
  • This company can be well to meet our needs on product quantity and delivery time, so we always choose them when we have procurement requirements.
    5 Stars By Camille from Norway - 2018.09.29 17:23
    Factory equipment is advanced in the industry and the product is fine workmanship, moreover the price is very cheap, value for money!
    5 Stars By Honorio from Johannesburg - 2017.04.08 14:55
    Write your message here and send it to us